安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- HIGHLIGHTS OF PRESCRIBING INFORMATION •Embryo-Fetal Toxicity: LIFYORLI . . .
LIFYORLI is used in combination with nab-paclitaxel Refer to the Prescribing Information of nab-paclitaxel for contraception and infertility information LIFYORLI can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8 1)]
- Corcept wins FDA nod for relacorilant in ovarian cancer
With a new U S | The FDA has given the all-clear to Corcept’s class-first Lifyorli (relacorilant) to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary
- FDA Approves Corcept’s Selective Glucocorticoid Receptor . . . - BioSpace
Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist (SGRA) Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, at least one of which included bevacizumab
- FDA Approves Lifyorli (relacorilant) Plus Nab-Paclitaxel for the . . .
Lifyorli Indication Usage Lifyorli is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab
- FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist . . .
Lifyorli (relacorilant), approved in combination with nab-paclitaxel, is the first U S Food and Drug Administration (FDA)-approved selective glucocorticoid receptor antagonist for adults with
- FDA approves relacorilant with nab-paclitaxel for platinum-resistant
On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc ), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the
- FDA approves Corcept Therapeutics Lifyorli for platinum-resistant . . .
FDA approves Lifyorli for platinum-resistant ovarian cancer after Phase III data showed improved survival versus chemotherapy alone
- Corcept Therapeutics receives FDA approval for Lifyorli™
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company pioneering the modulation of cortisol to treat severe disorders, today announced that the U S Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant) The drug is indicated for use in combination with nab
|
|
|